Clinical scenario

Treatment of Alport Syndrome in Autosomal Recessive Alport Syndrome

Autosomal recessive Alport syndrome is a genetically distinct subtype associated with a significant risk of progressive renal failure. Management is guided by specialist nephrology care with a focus on modifiable risk factors that drive disease progression.

Clinical situation

Individuals with autosomal recessive Alport syndrome should be managed by a nephrologist. Optimising risk factors for progressive renal failure — including hypertension, proteinuria, and dyslipidemia — is central to long-term care in this population.

Treatment approach

Early pharmacological intervention is recommended from the time of diagnosis — including before proteinuria has developed. A specific class of antihypertensive agent plays a key role in this strategy, alongside broader management of hypertension, proteinuria, and dyslipidemia. Full regimen, sequencing, and clinical decision logic available in the complete protocol →

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1681/ASN.2012020148

Individuals with autosomal recessive Alport syndrome should be managed by a nephrologist and have their risk factors for progressive renal failure optimized, including hypertension, proteinuria, and dyslipidemia.

Again, treatment with ACE inhibitors, from the time of diagnosis, even before the onset of proteinuria, may delay the onset of renal failure and improve life expectancy.

Evidence from a small retrospective registry analysis suggests that renin-angiotensin system blockade, for example with ACE inhibitors, delays renal failure and improves life expectancy in individuals with autosomal recessive Alport syndrome and may improve the outlook in carriers.

View source ↗